Articles tagged with Parkinsons Disease
Researchers at FAU Engineering have developed foot-mounted wearable sensors and a 3D depth camera that accurately measure how people walk, even in busy clinical environments. The study findings reveal that these technologies match the accuracy of traditional tools but are more scalable, remote, and cost-effective.
Researchers developed a computational tool to identify genetic vulnerabilities in memory-making brain cells linked to Alzheimer's. The 'seismic' algorithm integrates genetic data with single-cell RNA sequencing, revealing a detailed picture of affected cell types and their genetic programs.
A large international study reveals that women with a precursor condition to Parkinson's disease exhibit significantly less brain atrophy compared to men. The research suggests that estrogens may play a crucial role in protecting the brain from neurodegeneration.
Protein clumps associated with Parkinson's disease can actively break down ATP, draining brain cells of vital energy. Researchers discovered that these clumps transform into molecular machines when they bind to ATP, highlighting a new mechanism of damage.
A healthy microbiome promotes overall well-being, influencing areas like cognition, mood, immunity, and disease susceptibility. By incorporating proven dietary interventions, regular exercise, stress reduction, and adequate sleep, individuals can harness their microbiome for optimal health.
A study published in Annals of Neurology reveals a genetic connection between errors in the EPG5 gene, which causes Vici syndrome, and Parkinson's disease. Researchers found that individuals with rare errors in EPG5 were more likely to develop Parkinson's disease and dementia.
The UT Health San Antonio Center for Brain Health will unveil a 7-Tesla Terra.X MRI system, providing ultra-high-resolution brain images for diagnosing and studying conditions like dementia and Parkinson's. The technology expands what is possible in research and discovery.
A Barrow Neurological Institute study found a positive association between ambient trichloroethylene (TCE) and Parkinson's disease risk. The researchers identified a potential link between TCE exposure and an increased risk of Parkinson's disease, particularly in individuals living near facilities emitting the chemical.
Researchers at the University of Bath develop a peptide fragment that locks alpha-synuclein into its healthy shape, blocking toxic clumps that cause nerve cell death. The breakthrough demonstrates the potential of rational peptide design to transform large proteins into compact drug-like molecules.
Scientists have developed an imaging technique to visualize and quantify alpha-synuclein oligomers in human brain tissue, a major advance in Parkinson's research. The study found that oligomers exist in both healthy and Parkinson's brains, but are larger, brighter, and more numerous in disease samples.
A new study published in Biomaterials has developed a tiny, bioengineered system to deliver anti-inflammatory proteins to specific targets in the brain. The AstroCapsules, which are 300 micrometers in diameter, were confirmed to function when implanted into the brain and reduced neuroinflammation by measuring inflammatory biomarkers.
Researchers have found that tiny worms can help understand how memories fade, with dopamine playing a major role. Without dopamine, the worms held onto memories longer than usual, revealing that forgetting is a finely tuned process essential for staying focused and flexible.
Researchers highlight NAD+ supplements as potential key to healthier ageing and disease prevention, but call for larger studies. Early trials report improvements in memory, movement, and metabolism.
Research links oral bacteria to Parkinson's disease via the gut-brain axis, finding Streptococcus mutans produces metabolite imidazole propionate that contributes to disease progression. Targeting the oral-gut microbiome may offer a new therapeutic approach for Parkinson's treatment.
A Chinese Medical Journal study reviews the association between lipid metabolism and Parkinson’s disease. The research highlights how lipid disruptions contribute to α-Syn aggregation, mitochondrial dysfunction, and neuroinflammation, suggesting lipids as a promising therapeutic target for PD.
A study found that older adults with Parkinson's disease have a higher rate of brain amyloid positivity compared to younger patients, even without dementia. The researchers suggest this may indicate an accelerated transition from healthy cognition to dementia in PD patients.
Researchers from Trinity College Dublin discovered that nanoplastics can interfere with brain energy production by disrupting the electron transport chain in mitochondria. This finding may have implications for understanding neurodegenerative diseases and learning/memory issues.
Increasing PI31 levels demonstrates neuroprotective effects in mice, preventing neuronal degeneration and restoring synaptic function. The study also shows promise for treating Alzheimer's and slowing age-related cognitive decline.
Researchers at Rice University have developed a 'molecular magnifying glass' that allows them to visualize subtle environmental changes in proteins, which can indicate the earliest stages of diseases such as Alzheimer's, Parkinson's and cancer. This tool provides real-time monitoring of protein microenvironment changes in living cells.
Researchers used AI-powered video analysis to identify early motor function changes in Parkinson's disease and idiopathic REM sleep behavior disorder. The study found that even healthy-looking individuals had subtle movement alterations that could indicate underlying brain disorders.
A new study from Aarhus University reveals microscopic pores in brain cells formed by toxic α-synuclein oligomers, which constantly open and close like tiny revolving doors. This dynamic behavior may help explain why brain cells don't die immediately, but further research is needed to replicate the findings in biological tissue.
Researchers found that increased levels of EPS8 drive pathological protein aggregation and neurodegeneration in worms and human cell models. By reducing EPS8 activity, they prevented toxic protein accumulation and preserved neuronal function.
Scientists have discovered a distinct neurochemical signature that sets Parkinson's disease apart from essential tremor, two common movement disorders. In a new study published in Nature Communications, researchers identified unique chemical signaling patterns of dopamine and serotonin that distinguish these conditions.
Researchers found that a high fiber diet reduced Alzheimer's-related frailty and tremor in mice by restoring balance in the gut immune system. This discovery provides a potential new therapeutic pathway for the disease.
Researchers at POSTECH and Korea Brain Research Institute unveil NeuO's mechanism of selective neuron staining through PAK6 kinase phosphorylation. This breakthrough opens path for precise tracking and study of living neurons in brain.
Scientists at Gladstone Institutes discovered that overactivated dopamine neurons degenerate and die, leading to Parkinson's disease symptoms. Chronic activation of these cells can cause cell death, potentially triggered by genetic, environmental toxins, and compensating for lost neurons.
Dr. Rentería's Australian Parkinson's Genetics Study (APGS) includes nearly 20,000 volunteers, generating a comprehensive genetic database to understand Parkinson's disease variability. He incorporates wearable sensors and digital biomarkers to address clinical heterogeneity.
Researchers at Lund University found that specific sequences within non-coding genome help shape the developing human brain. Disrupting these sequences leads to abnormalities in gene activity and brain organoid growth, highlighting their importance in regulating genes and development.
Researchers discovered a significant association between metabolic syndrome and an increased risk of Parkinson's disease. The study found that people with metabolic syndrome were about 40% more likely to develop the disease than those without it.
Dr. David Rubinsztein shares his personal journey from childhood curiosity to discovering autophagy, a natural process that clears toxic proteins causing devastating neurodegenerative diseases. His research has established autophagy upregulation as a viable therapeutic strategy for conditions affecting millions worldwide.
Researchers developed a device and platform to measure Parkinson's disease symptoms quantitatively and reproducibly. The technology allows clinicians to guide treatments remotely and has been shown to be easy to use by patients.
Insilico Medicine has completed IND-enabling studies for ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders. The drug candidate demonstrated favorable PD/PK profiles and dose-dependent efficacy in motor functions in animal models.
Researchers have discovered a new approach for treating proteinopathies by targeting dysregulated nuclear speckles, which can lead to neuron degeneration. Pyrvinium pamoate has been shown to improve proteostasis in various disease models, including Alzheimer's, Parkinson's, and tauopathies.
Researchers found that low-oxygen environments can protect the brain and restore movement in mice with Parkinson's-like disease by reducing excess oxygen molecules. The study suggests that hypoxia could be a new approach to treating Parkinson's, potentially targeting cellular dysfunction rather than protein clumps.
A study led by Dr. Jessica Bernard at Texas A&M University investigates the role of the cerebellum in cognitive functions such as memory and language, with the aim of developing a non-invasive therapeutic approach using Theta burst simulation (TBS) to improve outcomes for older adults.
Researchers from Japan studied DJ-1's catalytic mechanism, revealing key amino acids involved in cPGA hydrolysis. Mutations in these residues revoked cPGA hydrolase activity, confirming the pathophysiological implications of DJ-1.
Researchers used machine learning to detect subtle behavioral changes in mouse models of Parkinson's disease, revealing that high-speed movements are the first affected behaviors. Levodopa treatment improves movement speed but not other attributes of these movements.
Researchers investigate how anxiety emerges and changes over the course of Parkinson's Disease, exploring its relationship to autonomic symptoms and brain regions like the amygdala. They aim to understand how functional changes in these areas may relate to behaviors.
Researchers developed an AI-based screening tool using pangrams to detect Parkinson’s disease with nearly 86 percent accuracy. The web-based test analyzes voice recordings for subtle patterns linked to the neurodegenerative disease, identifying potential warning signs.
Researchers developed a chemical probe that binds to damaged mitochondrial DNA, blocking enzymatic processes that lead to its degradation. This approach lessens mtDNA loss, preserving energy production in vulnerable tissues. The new molecule successfully reduced inflammation and maintained functional DNA despite chemical tagging.
Researchers now have access to high-value datasets that could transform our understanding of Parkinson’s and other neurodegenerative diseases. Data from 3 million human cells across 9 brain regions will help explore the brain at unprecedented resolution.
Scientists have discovered that microglia play a crucial role in regulating blood flow to the brain, and targeting them may improve blood flow deficits. The study suggests that restoring microglia function could prevent or reverse memory-stealing diseases caused by lack of adequate blood flow.
Researchers trained two dogs to distinguish between sebum swabs from people with and without Parkinson's disease, achieving sensitivity of up to 80% and specificity of up to 98%. The study suggests that dogs could help develop a quick, non-invasive method for early detection.
Scientists at University of South Australia developed a long-acting injectable formulation that delivers levodopa and carbidopa over a week, reducing the need for multiple daily tablets. The biodegradable formulation improves treatment outcomes and patient compliance, offering a potential game-changer for Parkinson's care.
Researchers found that Parkinson's disease symptoms on one side of the body can predict cognitive decline and psychiatric disorders. The study analyzed 80 studies to demonstrate the critical importance of personalized care tailored to individual disease profiles.
Non-invasive vagus nerve stimulation (nVNS) has demonstrated efficacy in reducing seizure frequency, improving mood, and enhancing motor recovery in various conditions. Future research should prioritize standardized protocols, large-scale trials, and biomarker development to personalize treatment.
A study by Universitat Oberta de Catalunya found that theatre-based interventions improve the emotional well-being of patients with Parkinson's, reducing depression and anxiety. Group activities foster emotional connections, increase empathy, and provide social support.
A new study led by Stanford Medicine suggests that inhibiting the LRRK2 enzyme could stabilize brain cell signaling and potentially halt cell death in Parkinson's disease. The researchers found that a kinase inhibitor, MLi-2, restored primary cilia on brain cells, enabling them to receive crucial signals and survive.
A new diagnostic tool uses AI to analyze handwriting signals, detecting subtle motor symptoms associated with Parkinson's disease. The device has shown an average accuracy of 96.22% in distinguishing patients from healthy individuals.
The new centre will investigate neural dynamics, developing novel interventions and devices to improve symptom relief and quality of life for people with brain disorders. It aims to harness neural dynamics for people with conditions like Parkinson’s disease or epilepsy.
Researchers used magnetoencephalography (MEG) technology to determine how levodopa affects brain signals in patients with Parkinson's disease. The study found that some patients experience 'off-target' effects of the drug, affecting brain regions beyond the intended dopamine-replacement therapy area.
Researchers identified hundreds of molecular markers in saliva associated with systemic pathological processes beyond the oral cavity. These markers can reflect genetic heritability of diseases such as prostate cancer, coronary disease, and Type 2 diabetes.
Researchers at the University of Sydney have identified a new brain protein involved in Parkinson's disease and found that targeting it with a drug treatment improved motor function in experimental models. The study suggests that this approach could slow or stop the progression of Parkinson's disease in humans.
Researchers analyzed single-cell transcriptomes from early, middle, and late stages of AD to identify subtle shifts in cellular activity. They found that mitochondria in vulnerable brain areas began to fail early in the disease, even before amyloid plaque buildup. The study also identified a gene called MEG3 involved in regulating mito...
Pernilla Wittung-Stafshede joins Rice University's Department of Chemistry as a professor, bringing expertise in metalloproteins and protein aggregation to enhance cancer research. Her focus is on understanding the role of copper-binding proteins in cancer metastasis and potential future therapies.
Researchers at La Jolla Institute for Immunology discovered that T cell reactivity is highest during the prodromal period in Parkinson's disease, which can last for decades before noticeable symptoms. This finding may guide the development of early diagnostic tools and provide a new timeline for Parkinson's disease detection.
Scientists have identified four biomarkers in ear wax that may indicate Parkinson's disease, and an AI-based screening model can detect them with 94% accuracy. This technology could pave the way for earlier diagnosis and improved patient care.
A study by King's College London found that specific changes in the microbiome are associated with cognitive decline in Parkinson's disease. The research suggests that oral-gut translocation may play an active role in worsening symptoms.
Researchers from the Mount Sinai Health System are presenting new studies on the impact of sleep on neurodegenerative diseases like Alzheimer's. The studies explore the relationship between obstructive sleep apnea and Alzheimer's pathogenesis, as well as the effects of sleep disruption on spatial learning and neuroinflammation.
Researchers at University of Virginia Health System discovered that an immune molecule called STING drives the formation of harmful plaques and protein tangles associated with Alzheimer's. Blocking STING protected lab mice from mental decline, suggesting a promising treatment target for neurodegenerative diseases.